With respect to novel agents, the ECHELON-2 study demonstrated that the combination of brentuximab vedotin and cyclophosphamide, doxorubicin, and prednisolone (CHP) showed significantly superior progression-free survival for CD30-positive PTCL, particularly ALK-positive ALCL (4). Here, ALK is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.